GSK benefits financially from a settlement with BioNTech, CureVac, and Pfizer over mRNA patent disputes, including upfront payments and future royalties.
BioNTech's acquisition of CureVac aims to enhance its oncology strategy by combining mRNA expertise, focusing on cancer immunotherapy and bispecific antibodies.
The settlement allows BioNTech and Pfizer to continue mRNA vaccine operations, while GSK continues separate patent enforcement in the US and Europe.
The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.
Patent Settlement Overview: GSK, BioNTech, CureVac, and Pfizer resolve US mRNA vaccine patent litigation, enabling global settlement potential after BioNTech’s CureVac acquisition.
Financial Terms: BioNTech will pay GSK $370 million upfront plus 1% US royalties and $130 million plus 1% royalties internationally post-acquisition, with CureVac receiving $370 million at closing.
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech GSK benefits financially from a settlement with BioNTech, CureVac, and Pfizer over mRNA patent disputes, including upfront payments and future royalties. Read the full IIPLA blog post: https://iipla.org/blog/gsk-gains-370-million-upfront-reduced-royalties-in-curevac-mrna-patent-settlement-agreement-with-pfizer-biontech